Blas COLL CRESPO,Dennis ANDRESS,Peter J. BRENNAN,James C. STOLZENBACH
申请号:
US14888195
公开号:
US20160074363A1
申请日:
2014.04.30
申请国别(地区):
US
年份:
2016
代理人:
摘要:
The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.